Klefström lab / Klefström lab

Klefström lab

Oncogenic signaling pathways as therapeutic targets in breast cancer

Our laboratory studies oncogene and tumor suppressor induced cancer-specific cellular programs, which cause therapeutic vulnerabilities in breast cancer.

Learn more

Pharmacological intervention of SARS-CoV-2 entry mechanisms by blockade of TMPRSS activity

The Klefström laboratory has been identifying and developing chemical and pharmacological inhibitors against hepsin/TMPRSS family members for a long time with the goal of preventing cancer invasion. Some of our drugs or drug-like molecules could be repurposed to prevent SARS-CoV-2 entry to cells, potentially offering a fast-track treatment option for the COVID-19 disease.

Read more

Public Outreach – Follow our team!

Klefström lab on facebook

Celebrating hard work and new opportunities. ... See MoreSee Less

View on Facebook

We feel privileged to have presented twice (a minisymposium and a poster session) at the annual AACR meeting. Thank you for joining us, and for the active Q and A session. We appreciate your curiosity and support.

... See MoreSee Less

View on Facebook

Great news! CancerIO is launching in Finland. 🥳

"The coming age of IO will have a transformative impact on fundamental and clinical cancer research, healthcare systems, business and, most importantly, on the lives of cancer patients."

Check out the whole article:

... See MoreSee Less

View on Facebook

Klefalabmeeting in the era of coronavirus ... See MoreSee Less

View on Facebook

Research Programs Unit/Translational Cancer Biology
& Medicum, Biomedicum Helsinki 1,
Medical Faculty, University of Helsinki

Haartmaninkatu 8
00290 Helsinki

University of Helsinki internal mailing address
P.O. Box 63
FI-00014 University of Helsinki

Tel. Lab +358 2 941 25494 (room B509)
Office +358 2 941 25493 (room B507b)
Junior office (room B503)
Fax +358 2 941 25610